According to Blueprint Medicines
's latest financial reports the company has S$1.00 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | S$0.93 B | -25.92% |
2022-12-31 | S$1.26 B | 96.41% |
2021-12-31 | S$0.64 B | -44.08% |
2020-12-31 | S$1.15 B | 76.92% |
2019-12-31 | S$0.65 B | -3.4% |
2018-12-31 | S$0.67 B | -25.06% |
2017-12-31 | S$0.90 B | 190.57% |
2016-12-31 | S$0.30 B | 34.67% |
2015-12-31 | S$0.23 B | 268.72% |
2014-12-31 | S$62.42 M | 2379.46% |
2013-12-31 | S$2.51 M |